News about Qiagen N V

Bridging Innovations QIAGENs Strides in Revamping Cancer Research and Global Diagnostics,
May 23 2025
VENLO, Netherlands ?? QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA), a front-runner in molecular testing solutions, is making strategic stri...

QIAGEN Expands Digital PCR Capabilities with New Lentivirus Solutions for Enhanced Quality Control in Cell and Gene T...
Apr 30 2025
In a remarkable stride towards enhancing quality control in the rapidly evolving fields of cell and gene therapy, QIAGEN (NYSE: QGEN; Frankfurt Prime ...

QIAGEN Poised to Elevate Lab Automation with Launch of Three Innovative Sample Preparation Instruments
Apr 15 2025
In a bold move set to reshape the future of laboratory operations, QIAGEN, a leading global provider of sample and assay technologies, has announced i...

QIAGEN Unveils Groundbreaking QIAprep Plasmodium Kit to Propel Malaria Research and Surveillance Forward
Apr 01 2025
In a significant advancement for malaria research and public health, QIAGEN N.V. headquartered in Venlo, Netherlands, has announced the launch of its ...

QIAGEN Unveils Ambitious Expansion in Barcelona Pioneering the Future of Infectious Disease and Precision Medicine Te...
Nov 29 2024
QIAGEN Expands QIAstat-Dx Operations with New Advanced Facility in Barcelona to Propel Infectious Diseases and Precision Medicine Testing In a bold st...

QIAGEN Expands QIAstat-Dx Operations in Barcelona to Enhance Infectious Disease Testing Amid Revenue Challenges
Nov 28 2024
In a strategic move to bolster its standing in the infectious diseases and precision medicine sectors, QIAGEN N.V. has announced plans to relocate its...

Pioneering Microbial Analysis Tools and Resilient Financial Performance QIAGEN Sets New Standards in Precision Diagno...
Nov 27 2024
As the landscape of molecular diagnostics continues to evolve, QIAGEN N.V. is making waves with the introduction of groundbreaking tools tailored for ...

QIAGEN Bolsters Microbiome Research and Diagnostic Capabilities through Strategic Partnerships and FDA Approvals,
Nov 12 2024
QIAGEN Advances Microbiome and Diagnostic Research through Strategic Collaborations and Innovations VENLO, Netherlands. QIAGEN, a leader in molecu...

Reinvesting in Resilience QIAGEN?s Remarkable Q3 2024 Growth Amidst Client Revenue Declines,
Nov 06 2024
QIAGEN: A Strong Q3 2024 Performance Defies Market Trends In an era characterized by fluctuating market conditions and shifting consumer demands, QIA...

QIAGEN Secures FDA Clearance for Rapid Meningitis and Encephalitis Diagnostic Tool
Nov 04 2024
In a pivotal development for emergency diagnostics, QIAGEN has received clearance from the U.S. Food and Drug Administration (FDA) for its QIAstat-Dx ...

Headline: Qiagen N V Sees Significant Decrease in Revenue and Income in Fourth Quarter of 2023
Mar 11 2024
The recent financial report for Qiagen N V paints a grim picture for the company*s financial health. The company*s income fell by a staggering -19.57%...